Withacnistin
| Name | Value |
|---|---|
| Weight | 512.643 g/mol |
| Zinc ID | ZINC1721697 |
| Smiles | CC(=O)OC[C@@]12CC[C@@H]3[C@H](C[C@H]4O[C@]45[C@H](O)C=CC(=O)[C@@]35C)[C@@H]1CC[C@@H]2[C@@H](C)[C@H]1CC(C)=C(C)C(=O)O1 |
| Molecular formula | C30H40O7 |
| Mode of inhibition | JAK and STAT inhibitor |
| CAS | 21902-99-8 |
Clinical Trials
References
Filter data
| Compound | Withacnistin |
| Experiment types | Co-immunoprecipitation, Colony formation assay , Immunofluorescence, Invasion assay , Luciferase activity, Luciferse activity, TUNEL, Tumor volume, Western Blot |
| Concentrations | 0.10, 0.30, 1.00, 10.00, 20.00, 3.00, 5.00 |
| Cell lines | A549, MDA-MB-468, MDA-MB-468 pLucSRE, MDA-MB-468 pLucTKS3, MDA-MB-468(xenograft), NIH 3T3, NIH3T3, RPMI-8226, TF-1, U-266, U266, breast tumor tissue |
| Organisms | Homo sapiens, Mus musculus |
| Animal models | ErbB2 |
| STAT proteins | IP: EGFR IB: STAT3, IP: EGFR IB: STAT5, IP: GP130 IB: STAT3, IP:EGFR IB:STAT3, IP:EGFR IB:STAT5, IP:GP130 IB:STAT3, STAT3, STAT5, p-STAT3, p-STAT5, p-STAT5A |
| Other | Bcl-xL, E-cadherin, EGFR, GP130, MCL-1, p-EGFR, p-PDGFR, pLuc-SRE, pLuc-TKS3, β-actin |